Rating Change
Guggenheim analysts reiterated a Buy rating on Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS) on July 21, 2026.
reiterateNASDAQ:TARS
Guggenheim Reiterates Buy Rating on Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
Rating Change Guggenheim analysts reiterated a Buy rating on Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS) on July 21, 2026. Market Context Tarsus Pharmaceuticals, Inc.
Market Context
Tarsus Pharmaceuticals, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $57.26 with a market capitalization of $3.5B.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tarsus Pharmaceuticals, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tarsus Pharmaceuticals, Inc. Common Stock
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | Guggenheim | Buy | N/A |
| Jul 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 04, 2026 | HC Wainwright & Co. | Buy | N/A |
| Feb 25, 2026 | Oppenheimer | Outperform | N/A |
| Feb 25, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TARS Stock Page
Frequently Asked Questions
What does a Buy rating mean for TARS?
A Buy rating from Guggenheim reflects the analyst's outlook on Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TARS forecast page.